In conclusion, the FolTAC platform, particularly the dual degrader technology, offers a promising, targeted, and less toxic approach to counteracting resistance in HER2-positive breast cancer, warranting further clinical investigation. This evidence concerns the gene ERBB2 and breast cancer.